Get started

Galecto

Homepage URL: galecto.com
Alternate names: Galecto, Inc., Galecto Biotech
Description: Swedish private biotechnology company
Country: DK
ROR: 01cjch873
Wikidata ID: entity/Q17083953
Crossref ID: 100017699
DOI: 10.13039/100017699
OpenAlex ID: F4320317585
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
2014 · Luca Richeldi, Roland M. du Bois, et al. · New England Journal of Medicine · 4,814
PDF
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
2022 · Ganesh Raghu, Martine Remy-Jardin, et al. · American Journal of Respiratory and Critical Care Medicine · 3,209
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
2019 · Oliver Distler, Kristin B. Highland, et al. · New England Journal of Medicine · 1,733
PDF
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline
2020 · Ganesh Raghu, Martine Remy-Jardin, et al. · American Journal of Respiratory and Critical Care Medicine · 1,109
PDF
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
2023 · Mary E. Rinella, Jeffrey V. Lazarus, et al. · Annals of Hepatology · 942
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation
2021 · Lorriana E. Leard, Are M. Holm, et al. · The Journal of Heart and Lung Transplantation · 890
PDF
Advancing the global public health agenda for NAFLD: a consensus statement
2021 · Jeffrey V. Lazarus, Henry E. Mark, et al. · Nature Reviews Gastroenterology & Hepatology · 801
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
2021 · Rachael A Evans, Hamish J C McAuley, et al. · The Lancet Respiratory Medicine · 701
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study
2022 · R A Evans, O C Leavy, et al. · The Lancet Respiratory Medicine · 430
PDF
Microglia-Secreted Galectin-3 Acts as a Toll-like Receptor 4 Ligand and Contributes to Microglial Activation
2015 · Miguel Angel Burguillos, Martina Svensson, et al. · Cell Reports · 376
PDF
Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management
2016 · Francis X. McCormack, Nishant Gupta, et al. · American Journal of Respiratory and Critical Care Medicine · 374
Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease
2019 · Antonio Boza-Serrano, Rocío Ruiz, et al. · Acta Neuropathologica · 369
Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study
2017 · Richard J Allen, Joanne Porte, et al. · The Lancet Respiratory Medicine · 316
PDF
Predictors of progression in systemic sclerosis patients with interstitial lung disease
2020 · Oliver Distler, Shervin Assassi, et al. · European Respiratory Journal · 257
PDF
High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease
2016 · Ian Ford, Anoop S.V. Shah, et al. · Journal of the American College of Cardiology · 251
PDF
Galectin‐3‐Binding Glycomimetics that Strongly Reduce Bleomycin‐Induced Lung Fibrosis and Modulate Intracellular Glycan Recognition
2016 · Tamara Delaine, Patrick Collins, et al. · ChemBioChem · 209
PDF
Immunosurveillance in clinical cancer management
2023 · Guido Kroemer, Timothy A. Chan, et al. · CA A Cancer Journal for Clinicians · 153
PDF
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
2021 · Kevin R. Flaherty, Athol U. Wells, et al. · European Respiratory Journal · 150
PDF
An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade
2019 · Lynda Vuong, Eleni Kouverianou, et al. · Cancer Research · 148
Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype
2020 · Yoshikazu Inoue, Robert J. Kaner, et al. · CHEST Journal · 137
PDF
Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement
2025 · Anna J. Podolanczuk, Gary M. Hunninghake, et al. · American Journal of Respiratory and Critical Care Medicine · 133
In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications
2021 · Maria Jimenez Ramos, Lucia Bandiera, et al. · iScience · 131
PDF
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease
2022 · Fredrik R. Zetterberg, Alison MacKinnon, et al. · Journal of Medicinal Chemistry · 114
Extracellular and intracellular small-molecule galectin-3 inhibitors
2019 · John Stegmayr, Fredrik Zetterberg, et al. · Scientific Reports · 108
PDF
Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement
2021 · Kerri I. Aronson, Sonye K. Danoff, et al. · American Journal of Respiratory and Critical Care Medicine · 104
PDF
Works count: 251
Citation count: 22,910
H-index: 56
I10-index: 145
2-year mean citedness: 13.37
Awards count: 1
Year
Topic
Type